Preview Mode Links will not work in preview mode

MPR Weekly Dose

  1. All Episodes
  2. MPR Weekly Dose 130 — FDA Vote on ALS Treatment; CPAP, BiPAP Recall; CRISPR Therapy for Hereditary Angioedema; Imfinzi Approved for Biliary Tract Cancer; Spevigo Approved

MPR Weekly Dose 130 — FDA Vote on ALS Treatment; CPAP, BiPAP Recall; CRISPR Therapy for Hereditary Angioedema; Imfinzi Approved for Biliary Tract Cancer; Spevigo Approved

Sep 9, 2022

Hello listener and welcome to episode 130 of the MPR Weekly Dose Podcast. This week we have news of the FDA’s vote on an ALS treatment; CPAP and BiPAP device recalls; Orphan Drug designation for a novel CRISPR therapy; Imfinzi gains new approval; and Spevigo is approved for pustular psoriasis flares.